You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

actinium

Showing 1 - 23 of 23
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Prostate Cancer Metastatic Trial in New York (Actinium-J591, Stereotactic Body Radiation Therapy, Androgen Deprivation Therapy)

Not yet recruiting
  • Prostate Cancer Metastatic
  • New York, New York
    Weill Cornell Medicine - New York Presbyterian Hospital
Oct 3, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Duarte (Actinium Ac 225-DOTA-Daratumumab, Daratumumab,

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Actinium Ac 225-DOTA-Daratumumab
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Jan 4, 2023

Uveal Melanoma, Metastatic Trial in Tampa (4.7 microCi 225Ac-MTI-201, 9.5 microCi of 225Ac-MTI-201, 19 microCi of 225Ac-MTI-201)

Recruiting
  • Uveal Melanoma
  • Metastatic
  • 4.7 microCi 225Ac-MTI-201
  • +11 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Aug 9, 2022

Metastatic Castration-resistant Prostate Cancer Trial in Finland, Netherlands, United Kingdom (BAY3546828, BAY2616505,

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Helsinki, Finland
  • +3 more
Sep 18, 2023

Prostatic Tumors, Adenocarcinoma Trial in United States (JNJ-69086420)

Recruiting
  • Prostatic Neoplasms
  • Adenocarcinoma
  • Duarte, California
  • +7 more
Aug 2, 2022

Metastatic Castration Resistant Prostate Cancer Trial in Houston (Ac225-PSMA I&T)

Recruiting
  • Metastatic Castration Resistant Prostate Cancer
  • Ac225-PSMA I&T
  • Houston, Texas
    Excel Diagnostics and Nuclear Oncology Center
Jan 27, 2022

B-ALL, DLBCL, B ALL Trial in New York (131-I Apamistamab, CAR T-cell)

Recruiting
  • B-ALL
  • +10 more
  • 131-I Apamistamab
  • CAR T-cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 7, 2022

Advanced Solid Tumours, Actinium-225, Antineoplastic Agents Trial in Australia, Canada, United States ([111In]-FPI-1547

Recruiting
  • Advanced Solid Tumours
  • +4 more
  • [111In]-FPI-1547 Injection
  • +3 more
  • Duarte, California
  • +12 more
Mar 2, 2022

Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma Trial in Irvine, Chicago, Boston

Not yet recruiting
  • Advanced Solid Tumor
  • +4 more
  • Irvine, California
  • +2 more
Nov 27, 2023

SCLC,Extensive Stage Trial in Omaha (RYZ101 Dose Level 1, RYZ101 Dose Level 2, RYZ101 Dose Level 3)

Recruiting
  • SCLC,Extensive Stage
  • RYZ101 Dose Level 1
  • +6 more
  • Omaha, Nebraska
    Nebraska Cancer Specialists
Nov 18, 2022

AML Trial in Puerto Rico, United States (Cytarabine (Phase 1 only), Lintuzumab-Ac225, Furosemide (Phase 1 only))

Completed
  • AML
  • Cytarabine (Phase 1 only)
  • +3 more
  • Los Angeles, California
  • +16 more
Feb 22, 2022

Acute Myeloid Leukemia, Relapsed Adult AML Trial in United States (Lintuzumab-Ac225, Venetoclax, Spironolactone)

Recruiting
  • Acute Myeloid Leukemia
  • Relapsed Adult AML
  • Lintuzumab-Ac225
  • +2 more
  • Los Angeles, California
  • +4 more
Feb 22, 2022

Acute Myeloid Leukemia, Relapsed Adult AML Trial (Lintuzumab-Ac225, Venetoclax, Azacitidine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Relapsed Adult AML
  • Lintuzumab-Ac225
  • +2 more
  • (no location specified)
Feb 22, 2022

Refractory Multiple Myeloma Trial in United States (Lintuzumab AC 225)

Terminated
  • Refractory Multiple Myeloma
  • Lintuzumab AC 225
  • Los Angeles, California
  • +4 more
Feb 22, 2022

Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma Trial in Duarte, Iowa City, New York

Recruiting
  • Advanced Solid Tumor
  • +13 more
  • Duarte, California
  • +3 more
Oct 25, 2022

Acute Myeloid Leukemia Trial (Ac-Lintuzumab)

Withdrawn
  • Acute Myeloid Leukemia
  • (no location specified)
Mar 6, 2019

Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute Trial in Canada, United States (Iomab-B, Conventional

Active, not recruiting
  • Acute Myeloid Leukemia
  • +8 more
  • Gilbert, Arizona
  • +23 more
Feb 22, 2022

GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease Trial in United States

Recruiting
  • GEP-NET
  • +6 more
  • Duarte, California
  • +3 more
Jul 28, 2022

Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck, Colorectal Cancer Trial in Omaha

Recruiting
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • +6 more
  • Omaha, Nebraska
    Urology Cancer Center/XCancer
Nov 29, 2022

Prostate Cancer Trial in Boston, Brooklyn, New York (225Ac-J591, Pembrolizumab, Androgen receptor pathway inhibitor)

Recruiting
  • Prostate Cancer
  • Boston, Massachusetts
  • +3 more
Sep 20, 2021

Prostate Cancer Metastatic, Castration Resistant Prostatic Cancer, Advanced Prostate Carcinoma Trial in Homburg

Recruiting
  • Prostate Cancer Metastatic
  • +2 more
    • Homburg, Saarland, Germany
      Dept. of Nuclear Medicine, Saarland University
    Apr 4, 2021

    Prostate Cancer Trial in Brooklyn, New York (225Ac-J591)

    Recruiting
    • Prostate Cancer
    • Brooklyn, New York
    • +1 more
    Nov 20, 2021

    Leukemia, Myelodysplastic Syndrome Trial in New York (ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195)

    Completed
    • Leukemia
    • Myelodysplastic Syndrome
    • ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Feb 24, 2015